Hengrui Medicine wins EMA acceptance for Hengrui Medicine stock
Published on 10/14/2026 at 06:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDrug pipeline and financial milestones
- European regulators accepted the fluzoparib application on October 8, 2026.
- Revenue reached CNY 15.46 billion in the first half of 2026, down 1.94 percent year on year.
- Hengrui Medicine stock was last at CNY 45.67 on Shanghai Stock Exchange on October 14, 2026 at 11:30 a.m. CST.
- The Novo Nordisk licensing deal has potential value of USD 2.60 billion.
Hengrui Medicine (ISIN CNE0000014W7) had its fluzoparib marketing authorization application accepted by the European Medicines Agency on October 8, 2026, according to Futu. The filing is the company's second independently developed innovative drug application submitted in the European Union, giving Hengrui Medicine stock a concrete international development milestone.
Three pipeline milestones in 2026
On September 23, 2026, Hengrui Medicine and its subsidiaries received clinical trial approvals for 10 drugs spanning oncology, metabolic disease and chronic kidney disease, including HRS-1596 and HRS-4729, according to BigGo Finance.
On September 29, 2026, Hengrui also disclosed a licensing arrangement giving Novo Nordisk rights outside Greater China for HRS-1596, with potential consideration of USD 2.60 billion, including USD 300.00 million upfront, as reported by Investing.com.
What does the pipeline mean?
The latest interim figures show why the pipeline matters. Hengrui reported revenue of CNY 15.46 billion in the first half of 2026, down 1.94 percent from the same period a year earlier, while attributable net profit rose 0.34 percent to CNY 4.47 billion, according to a Futu review. Net profit excluding non-recurring items fell 12.71 percent to CNY 3.73 billion, while fair-value gains reached CNY 843.00 million, including CNY 821.00 million linked to the Kailera stake.
Product mix provides the more constructive counterpoint. Innovative-drug sales increased 16.38 percent to CNY 8.81 billion in the first half, while non-oncology innovative-drug sales rose 73.97 percent to CNY 2.55 billion. That growth partly offset a 16.07 percent decline in generic-drug sales to CNY 5.14 billion.
International approvals shape the next phase
Hengrui's international strategy now combines licensing income with regulatory expansion. A preview published by Futu on October 12, 2026 highlighted planned data for HRS-4642 and two antibody-drug conjugates. In one cited Phase II study, HRS-4642 produced a confirmed objective response rate of 63.30 percent among 30 treatment-naive patients.
Hengrui Medicine was last at CNY 45.67 on the Shanghai Stock Exchange on October 14, 2026 at 11:30 a.m. CST. The finance quote placed market capitalization at CNY 291.3 billion and the 52-week range at CNY 41.89 to CNY 68.50, keeping the price 8.94 percent above the yearly low based on the same quote.
Hengrui Medicine key facts
- Company: Jiangsu Hengrui Medicine Co., Ltd.
- ISIN: CNE0000014W7
- WKN: A0M4DV
- Ticker: 600276
- Primary exchange: Shanghai Stock Exchange
- Shanghai Stock Exchange price as of October 14, 2026, 11:30 a.m. CST: CNY 45.67
- Market capitalization: CNY 291.3 billion as of October 14, 2026
- 52-week range: CNY 41.89-CNY 68.50 as of October 14, 2026
- Sector / Industry: Health care / pharmaceuticals
Market context: Market report Shanghai Composite.
